Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/29 05:53:45 pm
58.73 USD   +0.51%
04:17p DOW MOVERS : Xom, mrk
02:26pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2012 | 02:15pm CEST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media:
Ron Rogers, (908) 423-6449
or
Investors:
Carol Ferguson, (908) 423-4465


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
04:17p DOW MOVERS : Xom, mrk
02:26pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
01:03p MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
01:01p MERCK : European Commission Grants Marketing Authorisation for MSD’s ZEPAT..
12:55p MERCK : beats 2Q profit forecasts
12:46p MERCK : Announces Second-Quarter 2016 Financial Results
07/28 MERCK : Patent Issued for Caspofungin Composition (USPTO 9393307)
07/28 MERCK : and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to C..
07/27DJBayer Reports Higher Second-Quarter Profit, Raises Guidance
More news
Sector news : Pharmaceuticals - NEC
04:26pDJABBVIE : Results Boosted by Humira, Pipeline Growth
04:17pDJABBVIE : Results Boosted by Humira, Pipeline Growth
10:54aDJSANOFI : Profit Down as Diabetes Drug Sales Slip--Update
08:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07:45aDJSANOFI : Profit Down as Diabetes Drug Sales Slip
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:15a Big Week Climaxes With A First Look At GDP Along With Pharma, Energy Earnings
09:12a Merck earnings up 75%; Non-GAAP EPS up 8% in Q2; updates guidance
06:46a Merck beats by $0.02, beats on revenue
07/28 Notable earnings before Friday?s open
07/28 Apple Tops Dogs Of The Dow July Analysis
Advertisement
Financials ($)
Sales 2016 39 492 M
EBIT 2016 13 526 M
Net income 2016 6 428 M
Debt 2016 3 946 M
Yield 2016 3,16%
P/E ratio 2016 25,58
P/E ratio 2017 19,62
EV / Sales 2016 4,20x
EV / Sales 2017 4,19x
Capitalization 161 736 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 61,9 $
Spread / Average Target 5,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.10.62%161 736
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
BRISTOL-MYERS SQUIBB C..8.53%124 630
More Results